UBS has revised its price target for Clorox (CLX, Financial), lowering it from $176 to $154 while maintaining a Neutral rating for the stock. This adjustment comes as part of UBS's first-quarter outlook for the consumer staples sector, which has been facing challenges due to dwindling consumer demand and uncertain tariff implications in recent weeks. The bank notes that the approaching earnings season presents a particularly complex environment for consumer staples.
Despite these challenges, UBS highlights certain companies that are better positioned thanks to stronger or improving fundamental visibility. Among those, Coca-Cola (KO), Keurig Dr Pepper (KDP), Celsius (CELH), Monster Beverage (MNST), and Church & Dwight (CHD) are seen as promising choices. UBS emphasizes a preference for firms with clear or improving fundamentals, regardless of their current valuations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Clorox Co (CLX, Financial) is $157.54 with a high estimate of $189.00 and a low estimate of $134.00. The average target implies an upside of 15.16% from the current price of $136.80. More detailed estimate data can be found on the Clorox Co (CLX) Forecast page.
Based on the consensus recommendation from 21 brokerage firms, Clorox Co's (CLX, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Clorox Co (CLX, Financial) in one year is $148.53, suggesting a upside of 8.57% from the current price of $136.8. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Clorox Co (CLX) Summary page.
